Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children

• Published in: Antimicrobial agents and chemotherapy Vol. 62; no. 1
• Main Authors: Autmizguine, Julie, Melloni, Chiara, Hornik, Christoph P., Dallefeld, Samantha, Harper, Barrie, Yogev, Ram, Sullivan, Janice E., Atz, Andrew M., Al-Uzri, Amira, Mendley, Susan, Poindexter, Brenda, Mitchell, Jeff, Lewandowski, Andrew, Delmore, Paula, Cohen-Wolkowiez, Michael, Gonzalez, Daniel
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.01.2018
• Subjects: Adolescent; Adult; Anti-Bacterial Agents; Anti-Bacterial Agents - pharmacokinetics; Child; Child, Preschool; Clinical Therapeutics; Female; Humans; Infant; Infant, Newborn; Male; Methicillin-Resistant Staphylococcus aureus - drug effects; Prospective Studies; Staphylococcal Infections - drug therapy; Trimethoprim, Sulfamethoxazole Drug Combination; Trimethoprim, Sulfamethoxazole Drug Combination - pharmacokinetics; Young Adult; pharmacokinetics; methicillin-resistant Staphylococcus aureus; infants; children; trimethoprim; sulfamethoxazole

Trimethoprim (TMP)-sulfamethoxazole (SMX) is used to treat various types of infections, including community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) and Pneumocystis jirovecii infections in children. Pharmacokinetic (PK) data for infants and children are limited, and the optima...